<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C7FFCC23-E2D4-4940-811E-8D658D6A6C50"><gtr:id>C7FFCC23-E2D4-4940-811E-8D658D6A6C50</gtr:id><gtr:name>Western Infirmary, Glasgow</gtr:name><gtr:address><gtr:line1>Western Infirmary</gtr:line1><gtr:line2>Dumbarton Road</gtr:line2><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G11 6NT</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/07DC2DC9-8FEE-4D30-9309-28F95FBD0DA4"><gtr:id>07DC2DC9-8FEE-4D30-9309-28F95FBD0DA4</gtr:id><gtr:firstName>Nicholas</gtr:firstName><gtr:otherNames>I</gtr:otherNames><gtr:surname>Pitman</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G84%2F6704"><gtr:id>5DBA7E97-9A69-4F86-9AE3-26CD4BBD5DFE</gtr:id><gtr:title>The role of a novel cytokine (EBI3-p35) in asthma.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G84/6704</gtr:grantReference><gtr:abstractText>Asthma affects 100 to 150 million people worldwide and the incidence is increasing. It is a consequence of the body?s immune system mounting an inappropriate response within the lungs. Cells of the immune system are activated to secrete particular messenger molecules, which in turn leads to swelling and narrowing of the airways.
In the lungs the activation of particular groups of cells and release of specific cellular messengers results in inflammation and asthma, whereas suppression of these groups of cells coupled with the release of different molecules is associated with inhibition of this undesirable immune response.
Recent work suggests that a newly discovered molecule called EBI3-p35 acts to suppress inflammation and could therefore reduce airway inflammation.
We intend to investigate the role that EBI3-p35 plays in airway inflammation by studying a mouse model and examining samples from human asthmatics.
Current treatments for asthma are limited and can have significant side effects. In addition to improving our understanding of this significant condition EBI3-p35 could prove to be a new target for asthma therapy and in turn benefit large numbers of people.</gtr:abstractText><gtr:technicalSummary>Asthma is a chronic inflammatory disorder of the airways with complex interactions between a diverse population of cells mediated by a range of cytokines and inflammatory substances. The full range of cytokines associated with the regulation of airway inflammation is still not clear. Here I propose to investigate the role of a novel cytokine, EBI3-p35 in asthma.
 EBI3 (Epstein-Barr virus-induced gene 3) protein heterodimerises with the p35 subunit of IL-12 to form what we refer to as EBI3-p35. EBI3 and IL-12p35 are co-expressed in circumstances where the immune response is known to be down-regulated. The sponsor?s laboratory has recently cloned and expressed EBI3-p35 as a linked Fc fusion protein. Preliminary data has shown that murine EBI3-p35 promotes proliferation of CD4+CD25+ Treg cells and enhances their suppressor function. Combined with the finding that EBI3 and p35 expressions are up-regulated in asthmatics this has led to the hypothesis that EBI3-p35 plays a key role in asthma either via the promotion of CD4+CD25+ Treg cell function or by a direct anti-inflammatory effect.
 I will test this hypothesis by examining the level of EBI3-p35 expression in samples from asthmatics patients and investigating the role of this cytokine in a mouse model of asthma in vitro and in vivo. Sputum and peripheral blood samples from asthmatics and controls will be obtained through collaboration with Professor Neil Thomson. EBI3 and IL-12p35 expression will be measured by quantitative PCR and ELISA. The effect of EBI3-p35 on the cells in the samples, including Treg cells, will also be assessed. The role of EBI3-p35 will also be examined in vitro using ovalbumin specific lymphocytes. The in vivo role of EBI3-p35 will be studied using a well-established ovalbumin-induced murine asthma model in addition to an adoptive cell transfer model. The expression EBI3-p35 and other cytokines in the lung tissue and blood of treated mice will be evaluated by quantitative PCR and immunoass. EBI3-p35 will be introduced to the model at different time points. In addition, the model will also be studied in EBI3 knockout and transgenic mice.
 This project will not only increase our general understanding of the molecular mechanisms of asthma but may yield novel targets amenable to therapeutic intervention.</gtr:technicalSummary><gtr:fund><gtr:end>2008-05-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>178093</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>83496243-933F-4C89-A735-D5DF3662C6CF</gtr:id><gtr:title>IL-33 exacerbates antigen-induced arthritis by activating mast cells.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e8d926f151e1a5ca9c91291369227789"><gtr:id>e8d926f151e1a5ca9c91291369227789</gtr:id><gtr:otherNames>Xu D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>HhYbpZ2btbw</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8258CA02-2D95-40EF-9BE0-99DAD6B2CF2B</gtr:id><gtr:title>Nitric oxide induces CD4+CD25+ Foxp3 regulatory T cells from CD4+CD25 T cells via p53, IL-2, and OX40.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/27d6c70628e2e918f4cbee0dcadac415"><gtr:id>27d6c70628e2e918f4cbee0dcadac415</gtr:id><gtr:otherNames>Niedbala W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>BZi5JyKXkGt</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2D2A537A-99E9-40C3-A76D-3CEA2603E261</gtr:id><gtr:title>IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c46e2ecdbdcf081c5e7884ac05702bb5"><gtr:id>c46e2ecdbdcf081c5e7884ac05702bb5</gtr:id><gtr:otherNames>Kurowska-Stolarska M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>J324rKF5WRo</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G84/6704</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>